Cell viability was significantly increased by ABT-199 and ABT-737 treatments, under ABT-737 treatment especially patients diagnosed with EGPA did not respond to BCL-2 protein inhibition (Fig. 3a, b). Here, BCL2 is linked to eosinophilic granulomatosis with polyangiitis.